<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="/allregs/css/uswds.min.css">
    <link rel="stylesheet" href="/allregs/css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="/allregs/index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="/allregs/index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="/allregs/html/titles/title42.html">
                                    Title 42
                                </a><span>&nbsp/&nbsp</span>
                                <a href="/allregs/html/parts/42CFR414.html">Part 414
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 414.900  Basis and scope.
                            </h3>
                            <p class="depth1"><em>(a)</em> This subpart implements sections 1842(o), 1847A, and 1847B of the Act and outlines two payment methodologies applicable to drugs and biologicals covered under Medicare Part B that are not paid on a cost or prospective payment system basis.</p><p class="depth1"><em>(b)</em> Examples of drugs that are subject to the requirements specified in this subpart are:</p><p class="depth2"><em>(1)</em> Drugs furnished incident to a physician's service; durable medical equipment (DME) drugs.</p><p class="depth2"><em>(2)</em> Separately billable drugs at independent dialysis facilities not under the ESRD composite rate.</p><p class="depth2"><em>(3)</em> Statutorily covered drugs, for example--</p><p class="depth3"><em>(i)</em> Influenza.</p><p class="depth3"><em>(ii)</em> Pneumococcal and Hepatitis B vaccines.</p><p class="depth3"><em>(iii)</em> Antigens.</p><p class="depth3"><em>(iv)</em> Hemophilia blood clotting factor.</p><p class="depth3"><em>(v)</em> Immunosuppressive drugs.</p><p class="depth3"><em>(vi)</em> Certain oral anti-cancer drugs.
[69 FR 66424, Nov. 15, 2004, as amended at 70 FR 39093, July 6, 2005]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§.
          Code available <a href="https://github.com/anthonygarvan/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5
      </div>
    </div>
  </footer>
  </body>
</html>
